Treatment of myeloma cells with a potent and selective inhibitor of EP300/CBP, CCS1477 (inobrodib), evicted EP300/CBP from the enhancers of genes, inducing differentiation (Picaud et al. 2015). Here, EP300 is linked to plasma cell myeloma.